COVID-19 Drug Study for Out-Patient Care
Phase 2/3 of RHB-107 (Upamostat), a Serine Protease Inhibitor or Placebo for Treatment of COVID-19 Disease
HEALTHY PARTICIPANTS: No
CONDITION: COVID-19, Coronavirus
Purpose of the Study
The purpose of this study is to test the safety of the study drug RHB-107, also referred to as Upamostat, in two different doses to see if it can help people with early COVID-19. Participants in this study will receive either a high or low dosage of Upamostat and/or placebo and will take it by mouth once per day for 14 days.
Who Can Participate
Enrollment is competitive, and researchers hope to enroll a total of 310 participants in several U.S. sites.
Participants must be 18 years or older, started having symptoms or had a positive test for COVID-19 disease within three days from the planned start of study treatment, do not require hospitalization, and can use a smartphone may be eligible for the study. Eligible participants will take the study drug or placebo in a capsule by mouth once a day for up to 14 days. This study only has one in-person clinic visit; then, participants will be monitored closely for the study’s duration, up to 57 days, through phone apps, telehealth, and home health care visits.